Exploration of treatments for subarachnoid hemorrhage

Abstract

Subarachnoid hemorrhage (SAH) continues to be a leading cause of morbidity and mortality, with cerebral vasospasm as a common etiology of worse clinical progression. The purpose of this study was to evaluate and review the current literature concerning the effective treatment of SAH. The treatment options for SAH are expanding as new therapeutic targets are identified. Nimodipine is the primary medication prescribed due to its neuroprotective properties. In addition, certain drugs can enhance lymphatic flow and influence the recovery process, such as Dexmedetomidine, SSRIs, and DL-3-n-butylphthalide. Vasospastic and ischemic patients commonly undergo transluminal balloon angioplasty. Clinical trials have not yet provided conclusive evidence to support the use of magnesium or statins. Moreover, other agents such as calcium channel blockers, milrinone, hydrogen sulfide, exosomes, erythropoietin, cilostazol, fasudil, albumin, Eicosapentaenoic acid, corticosteroids, minocycline, and stellate ganglion blockade should be investigated further.